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Abstract
c-MYC overexpression is frequently observed in various cancers including colon cancer and regulates many biological activities such as aber-
rant cell proliferation, apoptosis, genomic instability, immortalization and drug resistance. However, the mechanism by which c-MYC confers
drug resistance remains to be fully elucidated. In this study, we found that the c-MYC expression level in primary colorectal cancer tissues cor-
related with the recurrence rate following 5-fluorouracil (5-FU)-based adjuvant chemotherapy. Supporting this finding, overexpression of exoge-
nous c-MYC increased the survival rate following 5-FU treatment in human colon cancer cells, and knockdown of endogenous c-MYC
decreased it. Furthermore, c-MYC knockdown decreased the expression level of ABCB5, which is involved in 5-FU resistance. Using a chromatin
immunoprecipitation assay, we found that c-MYC bound to the ABCB5 promoter region. c-MYC inhibitor (10058-F4) treatment inhibited c-MYC
binding to the ABCB5 promoter, leading to a decrease in ABCB5 expression level. ABCB5 knockdown decreased the survival rate following 5-FU
treatment as expected, and the ABCB5 expression level was increased in 5-FU-resistant human colon cancer cells. Finally, using a human colon
cancer xenograft murine model, we found that the combined 5-FU and 10058-F4 treatment significantly decreased tumorigenicity in nude mice
compared with 5-FU or 10058-F4 treatment alone. 10058-F4 treatment decreased the ABCB5 expression level in the presence or absence of 5-
FU. In contrast, 5-FU treatment alone increased the ABCB5 expression level. Taken together, these results suggest that c-MYC confers resis-
tance to 5-FU through regulating ABCB5 expression in human colon cancer cells.
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Introduction
Colorectal cancer is the most common malignant solid tumour world-
wide, and one of the leading causes of cancer-related deaths. 5-fluo-
rouracil (5-FU) is one of the main chemotherapeutic agents used to
kill colon cancer cells. In patients with advanced colon cancer, 5-FU
treatment reduces tumour size and prolongs survival. However, the
frequent emergence and survival of 5-FU-resistant colon cancer cells
often causes recurrence following 5-FU-based adjuvant chemother-
apy. Therefore, uncovering the mechanism underlying the acquisition
of 5-FU resistance might facilitate the identification of a predictive
marker of poor prognosis for 5-FU treatment, and provide a new
potential therapeutic target for the treatment of colorectal cancer.
The MYC family genes encode transcription factors that regulate
cell cycle, cell growth, differentiation, apoptosis, transformation,
genomic instability and angiogenesis [1, 2]. In particular, overexpres-
sion of c-MYC has been found in various cancer cells [2] including
colorectal cancer cells [3, 4] and is often associated with poor prog-
nosis [5]. Furthermore, c-MYC has been found to be involved in drug
resistance. Tumour cells resistant to cisplatin chemotherapy in vivo
display elevated c-myc expression [6], and c-myc antisense oligonu-
cleotides sensitize human colorectal cancer cells to chemotherapeutic
drugs [7]. Recent study has been shown that c-MYC overexpression
decreased the expression level of the bridging integrator 1, leading to
increased poly (ADP-ribose) polymerase 1 (PARP1) activity and resis-
tance to cisplatin [8]. However, the mechanism by which c-MYC regu-
lates drug resistance remains to be fully elucidated.
ATP-binding cassette (ABC) transporters are a family of
transporter proteins that contribute to drug resistance via
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ATP-dependent drug efflux pumps. Some ABC transporters confer
chemoresistance by causing the efflux of anti-cancer drugs [9,
10], and their expression levels correlate with the disease-free
survival rate of colorectal cancer patients after adjuvant chemo-
therapy [11]. Interestingly, recent studies have revealed that
MYCN regulates the expression levels of some ABC transporter
genes in neuroblastoma [12], and c-MYC regulates the expres-
sion levels of some ABC transporter genes in chronic myeloge-
nous leukaemia [13].
In this study, we identified ABCB5 as a novel c-MYC target gene
and examined the role of the c-MYC-ABCB5 axis in 5-FU resistance in
human colon cancer cells.
Materials and methods
Clinical colorectal cancer specimens
Patients with colorectal cancer who underwent surgical treatment at
Yamaguchi University and affiliated hospitals between April 2012 and
September 2012 were enrolled in this study. Detailed information about
these patients is presented in Table 1. Resected tumour specimens
were immediately taken from resected colons and kept at 80°C until
total RNA extraction. These samples were used in accordance with insti-
tutional guidelines and the Helsinki Declaration after obtaining informed
consent from all patients.
Real-time quantitative reverse transcription-
polymerase chain reaction (RT-PCR)
Resected tumour specimens were disrupted in Buffer RLT and homoge-
nized with shaking stainless steel beads (Qiagen, Valencia, CA, USA)
using Mixer Mill MM300 (Qiagen). After that, total RNA isolation was
performed with RNeasy Mini Kit according to the manufacturer’s proto-
col (Qiagen). Reverse transcription was performed with the Prime-
Script RT Master Mix (Perfect Real Time; TaKaRa, Shiga, Japan). The
cDNA template was amplified by real-time RT-PCR using the QuantiTect
SYBR Green PCR kit (Qiagen). The primers used are listed in Table S1.
The reaction condition was 95°C for 15 min., and followed by 50 cycles
of the following reaction: 95°C for 10 sec. and 60°C for 30 sec. The
quantitative RT-PCR was performed with LightCycler software ver 3.5
(Roche Applied Science, Tokyo, Japan) and data were evaluated using
the 2DDCT method [14].
Cell culture
The human colon cancer cell lines COLO-320, COLO205 and Caco-2
were purchased from the RIKEN Bioresource Center (Ibaraki, Japan).
These cell lines were maintained at 37°C in RPMI 1640 medium (COLO-
320 and COLO205) or MEM (Caco-2) containing 10% foetal calf serum
(FCS) in a humidified atmosphere with 5% CO2. To establish 5-FU-resis-
tant Caco-2 cells, Caco-2 cells were maintained in MEM containing 10%
FCS with continuous exposure to 5-FU at the concentration of 2 lM for
12 weeks.
Reagents
5-fluorouracil and cis-Diammineplatinum (II) dichloride (cisplatin) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). 10058-F4 was
purchased from Calbiochem (San Diego, CA, USA). 5-FU and 10058-F4
were dissolved in dimethyl sulfoxide (DMSO) and stored at 4°C. Cis-
platin was dissolved in 0.9% sodium chloride just before use and stored
at 4°C.
Knockdown of target gene expression by small
interfering RNA transfection
Scrambled (control), c-MYC small interfering RNA (siRNA; Thermo Sci-
entific Dharmacon, Lafayette, CO, USA), ABCB5 siRNA (Life Technolo-
gies, Carlsbad, CA, USA) or ABCC5 siRNA (Life Technologies) was
transfected as described previously [15].
Overexpression of exogenous c-MYC
We purchased a pcDNA3 vector containing a full-length cDNA that
encodes human c-MYC (pcDNA3-c-MYC) from Addgene (Cambridge,
MA, USA), and the pcDNA3 empty vector was kindly provided by the
Yamaguchi University Center for Gene Research. Transfection of
pcDNA3-c-MYC or pcDNA3 empty vector into COLO205 cells was per-
formed with Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s protocol.
Preparation of nuclear extracts and whole cell
lysates
Nuclear extracts were prepared from COLO205 and COLO-320 cells
using Nuclear Complex Co-IP Kit (Active Motif, Carlsbad, CA, USA)
according to the manufacturer’s protocol. Whole cell lysates from
COLO-320, Caco-2 and 5-FU-resistant Caco-2 cells were prepared using
1% (v/v) Nonidet P-40 (NP-40) lysis buffer as described previously
[16]. Caco-2 xenografts was lyzed with RIPA buffer (50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1% (v/v) NP-40, 0.5% sodium deoxycholate,
0.1% SDS, 1 X protease inhibitor cocktail) and homogenized with shak-
ing stainless steel beads (Qiagen) using Mixer Mill MM300 (Qiagen).
Western blotting
Western blotting was performed as described previously [16] using
nuclear extracts or whole cell lysates. The following primary and sec-
ondary antibodies were used. The primary antibodies were mouse
monoclonal c-MYC antibody (9E10; Santa Cruz Biotechnology, Inc., Dal-
las, TX, USA), goat polyclonal ABCB5 antibody (46-620; ProSci Inc., Po-
way, CA, USA), goat polyclonal MRP5 antibody (Abcam, Cambridge,
MA, USA), rabbit monoclonal BCRP/ABCG2 antibody (Abcam), rabbit
monoclonal PCNA antibody (D3H8P XP; Cell Signaling, Danvers, MA,
USA), mouse monoclonal PARP1 antibody (F-2; Santa Cruz Biotechnol-
ogy, Inc.) and mouse monoclonal a-Tubulin antibody (B-7; Santa Cruz
Biotechnology, Inc.). The secondary antibodies were antimouse
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Table 1 Relationship between recurrence and clinicopathological characteristics of colorectal patients treated with 5-FU-based adjuvant
chemotherapy after curative surgery
Non-Recurrence Recurrence
No. of patients 13 7 P
Gender
Male 7 (53.8%) 3 (42.9%) N.S.
Female 6 (46.2%) 4 (57.1%)
Age 71.1  8.1 75.0  4.0 N.S.
Location
Right 7 (53.8%) 2 (28.6%) N.S.
Left 2 (15.4%) 2 (28.6%)
Rectum 4 (30.8%) 3 (42.8%)
Histological grade
Well 1 (7.7%) 1 (14.3%) N.S.
Moderate 12 (92.3%) 5 (71.4%)
Poor 0 (0%) 1 (14.3%)
Invasion depth
T2 1 (7.7%) 0 (0%) N.S.
T3 12 (92.3%) 6 (85.7%)
T4 0 (0%) 1 (14.3%)
Lymphatic metastasis
Positive 7 (53.8%) 5 (71.4%) N.S.
Negative 6 (46.2%) 2 (28.6%)
Lymphatic invasion
Positive 13 (100%) 5 (71.4%) N.S.
Negative 0 (0%) 2 (28.6%)
Venous invasion
Positive 8 (61.5%) 3 (42.8%) N.S.
Negative 5 (38.5%) 4 (57.1%)
Stage (UICC, 2009)
IIA 3 (23.1%) 0 (0%) N.S.
IIB 3 (23.1%) 2 (28.6%)
IIIA 1 (7.7%) 0 (0%)
IIIB 2 (15.4%) 3 (42.8%)
IIIC 4 (30.8%) 2 (28.6%)
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immunoglobulins conjugated to horseradish peroxidase (Igs-HRP), anti-
rabbit Igs-HRP and anti-goat Igs-HRP (Dako, Carpinteria, CA, USA).
Cell viability assay (WST-8 assay)
Cell viability was evaluated using Cell Count Reagent SF (Nacalai Tes-
que; Kyoto, Japan) according to the manufacturer’s protocol. Cell viabil-
ity was determined by measuring the absorbance at 450 nm using a
microplate reader (Model 550; Bio-Rad Laboratories, Hercules, CA,
USA).
Semi-quantitative RT-PCR
Total RNA isolation, synthesis of cDNA and subsequent PCR were per-
formed as described previously [15]. DNA sequences of the primers
used for RT-PCR are listed in Table S2. Reaction conditions for each
primer set were 50°C for 30 min. and 94°C for 2 min. followed by 20
cycles (MDR1, GAPDH), 24 cycles (c-MYC, ABCB5), 25 cycles (ABCC4,
ABCC5) or 27 cycles (MRP1) of the following reaction: denaturing step
at 94°C for 30 sec.; annealing at 54.5°C (ABCB5), 55°C (GAPDH),
57.5°C (c-MYC) or 60°C (MDR1, MRP1, ABCC4, ABCC5) for 30 sec.;
and extension at 72°C for 30 sec. PCR products were analyzed on a
1% agarose gel containing ethidium bromide and detected using a UV
transilluminator.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed with ChIP-ITTM
Express Enzymatic (Active Motif) according to the manufacturer’s proto-
col. Normal mouse IgG (sc-2027) and mouse monoclonal anti-c-MYC
(N-262) antibody were used for ChIP (Santa Cruz Biotechnology, Inc.).
Each region containing a c-MYC-binding site within the ABCB5 promoter
was amplified using each primer set. DNA sequences of the primers
used for the ChIP assay are listed in Table S3. The reaction condition
was 28 cycles of denaturation at 94°C for 20 sec., annealing at 54°C
for 30 sec. and extension at 72°C for 30 sec. PCR products were
resolved on a 3% agarose gel containing ethidium bromide and
detected using an ultraviolet transilluminator.
Nude mouse xenograft model and in vivo
experiments
Seven-week-old female BALB/c athymic Nu/Nu mice were purchased
from Japan SLC Inc. (Shizuoka, Japan). A mixture of 1 9 106 Caco-2
cells and Matrigel (BD Biosciences, San Jose, CA, USA) was subcuta-
neously injected to the right side of the back of the mice under
anaesthesia. Tumour size was measured using a caliper, and the vol-
ume was calculated using the following formula: volume = length 9
width 9 height. When the tumour size was about 1000 mm3,
the mice were daily treated with DMSO as a vehicle control, 5-FU
(10 mg/kg), 10058-F4 (20 mg/kg) or 5-FU (10 mg/kg) and 10058-F4
(20 mg/kg) by intraperitoneal administration for 2 weeks. The tumour
volume was measured on day 0, 3, 5, 7, 10 and 14 following each
treatment. Tumour tissues were used for immunofluorescent and
western blotting analyses. All animal experiments in this study were
approved by the Institutional Animal Care and Use Committee of
Yamaguchi University.
Immunofluorescence staining
The excised human colon cancer xenografts were fixed with a 10% for-
malin neutral buffer solution (Wako; Osaka, Japan) for 24 hrs at room
temperature and were placed in 10% sucrose, 20% sucrose and 30%
sucrose for 6 hrs each at 4°C with shaking. The samples were embed-
ded in OCT compound, and the embedded samples were sectioned
(5 lm) for immunofluorescence staining. The sections were first incu-
bated with blocking reagent including 1% Triton X-100 for 1 hr at room
temperature. After aspirating the blocking solution, the sections were
incubated with a rabbit monoclonal antibody against Ki67 [SP6] (Ab-
cam) or a goat polyclonal antibody against ABCB5 (Abcam) at 4°C over-
night. The sections were rinsed three times with 19 PBS for 5 min.
each and were incubated with Alexa Fluor 555F (ab’)2 fragment of goat
anti-rabbit IgG (H+L) (Life Technologies) or donkey anti-goat IgG-TR
(Santa Cruz Biotechnology, Inc.) for 1 hr at room temperature in the
dark. The sections were rinsed three times with 19 PBS for 5 min.
each. Nuclei were detected using DAPI staining. After washing three
times with 19 PBS for 5 min. each, the sections were mounted with
Fluorescent Mounting Medium (Dako). The images were acquired using
the 360  20 nm (blue) and 545  12.5 nm (red) excitation filters on
a BZ-X710 All-in-One fluorescence microscope (KEYENCE Japan, Osaka,
Japan).
Detection of apoptotic cells by TUNEL method
The paraffin tissue sections were deparaffinized by heating at room
temperature for 5 min. to melt the wax, then immersed in xylene
and washed in a graded ethanol. The sections were rinsed three
times with 19 PBS for 5 min. each and were incubated with protein-
ase K at 37°C for 30 min., and then with PBS including 0.1% Triton
X-100 for 2 min. After washing with PBS, apoptotic cells were
detected with TUNEL method using In situ Cell Death Detection Kit,
TMR red (Roche Applied Science, Waltham, MA, USA) according to
the manufacturer’s protocol. Nuclei were detected using DAPI stain-
ing. After washing three times with 19 PBS for 5 min. each, the
sections were mounted with Fluorescent Mounting Medium (Dako).
The images were acquired using the 360  20 nm (blue) and
545  12.5 nm (red) excitation filters on a BZ-X710 All-in-One fluo-
rescence microscope (KEYENCE Japan).
Detection of apoptotic dead cells by flow
cytometric analysis
Caco-2 cells were treated with DMSO, 5-FU (10 lM), 10058-F4
(32 lM), 5-FU (10 lM) and 10058-F4 (32 lM) for 72 hrs. The cells
were resuspended in binding buffer containing Annexin V-FITC and PI
using FITC Annexin V Apoptosis Detection Kit I (BD Biosciences)
according to the manufacturer’s protocol. Annexin V-FITC and PI stain-
ing were quantified using a FACSCalibur flow cytometer (Becton Dicken-
son, Franklin Lakes, NJ, USA).
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Statistical analysis
Statistical analyses were performed with SPSS for Windows ver. II. Data
are expressed as means  SD. To compare the experimental groups,
Student’s t-test was performed. Data from clinical colorectal cancer
specimens were analysed using Pearson correlation calculations. Kap-
lan–Meier curves were compared using the log-rank test. P < 0.05 (∗)
or P < 0.01 (∗∗) was considered to be statistically significant.
Results
High expression of c-MYC in surgically resected
primary colorectal cancer tissues correlates with
recurrence following 5-FU-based adjuvant
chemotherapy
To investigate whether c-MYC expression in surgically resected pri-
mary colorectal cancer tissues correlates with recurrence following
5-FU-based adjuvant chemotherapy, we selected 20 patients who
had received 5-FU-based adjuvant chemotherapy after curative sur-
gery. Total RNAs were purified from surgically resected tumours
before 5-FU-based adjuvant chemotherapy and used for real-time
RT-PCR. As shown in Figure 1A, the c-MYC expression level in sur-
gically resected primary colorectal cancer tissues of patients with
recurrence following 5-FU-based adjuvant chemotherapy was signifi-
cantly higher than that of patients without recurrence (P = 0.002).
Clinicopathological characteristics of these colorectal cancer patients
are presented in Table 1. As shown in Table 1, all clinicopathological
characteristics did not correlate with recurrence following 5-FU-
based adjuvant chemotherapy. Furthermore, ROC curve analysis was
used to obtain the optimal cut-off value of c-MYC mRNA levels in
primary surgical cancer tissues of colorectal cancer patients. As
shown in Figure 1B and Table 2, the Kaplan–Meier plot showed that
patients with the high expression level of c-MYC mRNA had a poorer
recurrence-free survival rate than that of the patients with low
expression level of c-MYC mRNA (P = 0.0004). These results sug-
gest that the high c-MYC expression level in primary colorectal can-
cer tissues correlates with the recurrence rate following 5-FU-based
adjuvant chemotherapy.
c-MYC modulates 5-FU resistance in human
colon cancer cells
To determine whether c-MYC is involved in 5-FU resistance, we inves-
tigated the effect of c-MYC overexpression or knockdown on the sur-
vival rate following 5-FU treatment in human colon cancer cells. We
selected COLO205 cells for exogenous c-MYC overexpression,
because parental COLO205 cells had low c-MYC expression level in
the nucleus, but not in the cytoplasm (data not shown). COLO205
cells were transfected with pcDNA3-empty vector or pcDNA3-c-MYC,
and exogenous c-MYC overexpression was confirmed by western
blotting (Fig. 2A). As shown in Figure 2B, c-MYC overexpression in
COLO205 cells significantly increased the survival rate following 5-FU
treatment compared with control cells. Furthermore, we selected
COLO-320 cells for knockdown of endogenous c-MYC, because
parental COLO-320 cells presented a high c-MYC expression level in
the nucleus, but not in the cytoplasm (data not shown). COLO-320
A
B
Fig. 1 Relationship between c-MYC expression level in surgically
resected primary colorectal cancer tissues and recurrence following 5-
FU-based adjuvant chemotherapy. (A) c-MYC expression levels in clini-
cal colorectal cancer tissues were determined by real-time RT-PCR, and
were compared between the recurrence (n = 7) and non-recurrence
group (n = 13) following 5-FU-based adjuvant chemotherapy. The ratio
of c-MYC to GAPDH expression was normalized to the lowest value
obtained in non-recurrence group. Horizontal lines indicate the mean c-
MYC expression level. (B) Kaplan–Meier analysis for recurrence-free
survival rate following 5-FU-based adjuvant chemotherapy.
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Table 2 Relationship between c-MYC expression and clinicopathological characteristics of colorectal patients treated with 5-FU-based adjuvant
chemotherapy after curative surgery
c-MYC expression Low High
No. of patients 11 9 P
Gender
Male 7 (63.6%) 3 (33.3%) N.S.
Female 4 (36.4%) 6 (66.7%)
Age 70.8  8.7 74.3  3.7 N.S.
Location
Right 6 (54.5%) 3 (33.3%) N.S.
Left 1 (9.1%) 3 (33.3%)
Rectum 4 (36.4%) 3 (33.3%)
Histological grade
Well 1 (9.1%) 1 (11.1%) N.S.
Moderate 10 (90.9%) 7 (77.8%)
Poor 0 (0%) 1 (11.1%)
Invasion depth
T2 0 (0%) 1 (11.1%) N.S.
T3 11 (100%) 7 (77.8%)
T4 0 (0%) 1 (11.1%)
Lymphatic metastasis
Positive 6 (54.5%) 6 (66.7%) N.S.
Negative 5 (45.5%) 3 (33.3%)
Lymphatic invasion
Positive 11 (100%) 7 (77.8%) N.S.
Negative 0 (0%) 2 (22.2%)
Venous invasion
Positive 7 (63.6%) 4 (44.4%) N.S.
Negative 4 (36.4%) 5 (55.6%)
Stage (UICC, 2009)
IIA 2 (18.2%) 1 (11.1%) N.S.
IIB 3 (27.3%) 2 (22.2%)
IIIA 1 (9.1%) 0 (0%)
IIIB 2 (18.2%) 3 (33.3%)
IIIC 3 (27.3%) 3 (33.3%)
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cells were transfected with scrambled siRNA or c-MYC siRNA, and
the knockdown of endogenous c-MYC in nuclear extracts of COLO-
320 cells was confirmed by western blotting (Fig. 2C). As shown in
Figure 2D, c-MYC knockdown significantly decreased the survival
rate following 5-FU treatment when compared with control cells. As
expected, the survival rate following 5-FU treatment in parental
COLO-320 cells was higher than that in parental COLO205 cells, and
there was correlation between c-MYC expression level and the sur-
vival rate following 5-FU treatment (data not shown). These results
indicate that c-MYC modulates 5-FU resistance in human colon can-
cer cells.
c-MYC regulates ABCB5 expression through its
binding to the ABCB5 promoter
To identify the ABC transporter gene regulated directly by c-MYC,
we investigated the effect of c-MYC knockdown on the expres-
sion levels of 5 ABC transporter genes, which are closely
involved in resistance to chemotherapeutic agents including 5-FU
[17–23]. Total RNAs were purified from COLO-320 cells trans-
fected with scrambled siRNA or c-MYC siRNA and used for RT-
PCR to assess MDR1, MRP1, ABCB5, ABCC4 and ABCC5 expres-
sion levels. The results showed that c-MYC knockdown decreased
ABCB5, ABCC4 and ABCC5 expression levels, whereas MDR1 and
MRP1 expression levels increased or nearly remained unchanged
(Fig. 3A). Among ABCB5, ABCC4, and ABCC5, ABCB5 expression
level was decreased the most by c-MYC knockdown. Therefore,
we focused on ABCB5 as a possible c-MYC target gene. To
investigate whether c-MYC directly binds to the ABCB5 promoter,
a ChIP assay was performed with COLO-320 cells. As shown in
Figure 3B, there were four locations of c-MYC-binding sites (CAT-
GTG) within the ABCB5 promoter region, spanning from 5000
to +1500 base pairs (bp) with respect to the transcription start
site. They were localized at 3415/3410, 1812/1807, 87/
82 and +1101/+1106 bp (Fig. 3B). We also searched other c-
MYC-binding sites (CACGTG and CACGCG), but these binding
sites were not present in this region. The results showed that c-
MYC bound to two binding sites within the ABCB5 promoter
(3415/3410 and 87/82) (Fig. 3C). These results suggest
that ABCB5 is a c-MYC target gene.
c-MYC inhibitor, 10058-F4, decreased the ABCB5
expression level through the inhibition of c-MYC
binding to the ABCB5 promoter
It is well known that c-MYC protein oncogenic activity requires dimer-
ization with MAX [24]. To assess the importance of c-MYC-MAX
complex-targeted DNA binding on the induction of ABCB5 expres-
sion, we used the c-MYC small molecule inhibitor, 10058-F4, to inhi-
bit the binding of c-MYC to target DNA by preventing c-MYC-MAX
heterodimerization [25]. A ChIP assay, RT-PCR and western blotting
were performed with COLO-320 cells treated with DMSO or 10058-F4
for 48 hrs. 10058-F4 treatment decreased the amount of c-MYC
binding to the ABCB5 promoter (Fig. 4A). As expected, 10058-F4
treatment decreased ABCB5 expression at mRNA and protein levels
(Fig. 4B and C). Furthermore, we investigated the effect of 10058-F4
treatment on the expression levels of other 5-FU resistance-involved
ABC transporters, ABCC5 and ABCG2 [26]. Although 10058-F4
treatment decreased ABCC5 expression, the expression level of
ABCC5 protein was very low in COLO-320 cells (Fig. 4D, upper
panel). ABCG2 protein was expressed in COLO-320 cells, and
10058-F4 treatment did not decrease ABCG2 expression (Fig. 4D,
middle panel). These results suggest that c-MYC positively regulates
the expression of ABCB5 through c-MYC binding to the ABCB5
promoter.
ABCB5 is closely involved in 5-FU resistance
To elucidate the role of ABCB5 in 5-FU resistance, we examined
the effect of ABCB5 knockdown on the survival rate following 5-
FU treatment in COLO-320 cells. The knockdown of endogenous
Table 2. Continued
c-MYC expression Low High
No. of patients 11 9 P
Chemotherapy regimen
UFT 4 (36.4%) 4 (44.4%) N.S.
Xeloda 2 (18.2%) 2 (22.2%)
TS-1 5 (45.5%) 3 (33.3%)
Recurrence
+ 0 (0%) 7 (77.8%) 0.0002
 11 (100%) 2 (22.2%)
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ABCB5 was confirmed in COLO-320 cells transfected with ABCB5
siRNA by western blotting (Fig. 5A). In ABCB5-silenced COLO-
320 cells, the survival rate following 5-FU treatment was signifi-
cantly decreased compared with that in control cells, and ABCB5
knockdown had no effect on the survival rate following cisplatin
treatment (Fig. 5B). Moreover, 5-FU-resistant Caco-2 cells pre-
sented a high ABCB5 expression level and a significantly high
survival rate following 5-FU treatment compared with those of
parental Caco-2 cells (Fig. 5C and D). These results suggest that
ABCB5 is closely involved in 5-FU resistance in human colon
cancer cells.
The combined treatment of 5-FU and 10058-F4
decreased tumorigenicity in nude mice
To investigate the effect of the combined treatment of 5-FU and
10058-F4 on tumorigenicity in nude mice, a human colon cancer
A B
DC
Fig. 2 Effect of c-MYC overexpression or knockdown on the survival rate following 5-FU treatment. (A) Nuclear extracts were prepared from
COLO205 cells transfected with pcDNA3 empty vector or pcDNA3-c-MYC, and nuclear c-MYC and PARP1 expression was detected by western blot-
ting. PARP1 was used to assess the total amount of nuclear extracts loaded on the gel. The intensity of each band was quantified using ImageJ
analysis software. The intensity of other bands was quantified in the same way. The number under the band in the upper right lane shows the ratio
of c-MYC to PARP1 band intensity normalized to the value obtained in control cells. N.E., nuclear extracts. (B) COLO205 cells transfected with
pcDNA3 empty vector or pcDNA3-c-MYC were treated with DMSO or 5-FU at various concentrations (1, 2, 5 and 10 lM) for 48 hrs, followed by a
WST-8 assay to assess survival rates. The survival rate was normalized to that in the pcDNA3 empty vector or pcDNA3-c-MYC transfected cells
treated with DMSO as a vehicle control. *P < 0.05; **P < 0.01, significantly different (n = 4). (C) Nuclear extracts were prepared from COLO-320
cells transfected with scrambled siRNA or c-MYC siRNA. Nuclear c-MYC and PARP1 expression was detected by western blotting. PARP1 was used
to assess the total amount of nuclear extracts loaded on the gel. The number under the band in the upper right lane shows the ratio of c-MYC to
PARP1 band intensity normalized to the value obtained in control cells. N.E., nuclear extracts. (D) COLO-320 cells transfected with scrambled siRNA
or c-MYC siRNA were treated with DMSO or 5-FU at various concentrations (1, 2, 5 and 10 lM) for 48 hrs, followed by a WST-8 assay to assess
the survival rate. The survival rate was normalized to that in the scrambled siRNA or c-MYC siRNA transfected cells treated with DMSO as a vehicle
control. *P < 0.05; **P < 0.01, significantly different (n = 4).
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xenograft murine model was developed. As shown in Figure 6A and
B, 5-FU or 10058-F4 treatment decreased tumour volumes compared
with the control. Furthermore, the combined treatment of 5-FU and
10058-F4 significantly decreased tumorigenicity in nude mice com-
pared with 5-FU or 10058-F4 treatment (P < 0.05). The ratio of Ki67-
positive cells was decreased, and the ratio of TUNEL-positive cells
was increased in 5-FU, 10058-F4 and the combined 5-FU and 10058-
F4 treatment groups compared with the control (Fig. 6C–F). The com-
bined treatment of 5-FU and 10058-F4 tended to decrease the Ki67-
positive ratio and to increase the TUNEL-positive ratio the most. Fur-
thermore, 10058-F4 treatment and the combined 5-FU and 10058-F4
treatment decreased the ABCB5 expression level when compared with
the control (Fig. 6G and H). Conversely, 5-FU treatment alone
increased the ABCB5 expression level when compared with the con-
trol (Fig. 6G and H).
Discussion
Previous reports indicating that c-MYC was overexpressed in many
types of cancers and contributed to drug resistance motivated us
to investigate the role of c-MYC expression in 5-FU resistance in
this study. First, we performed real-time RT-PCR using surgically
resected tumours from 20 patients with colorectal cancer who were
subsequently treated with 5-FU-based adjuvant chemotherapy after
curative surgery. Our results showed that the c-MYC expression
level in resected colorectal cancer tissues markedly correlated with
recurrence following 5-FU-based adjuvant chemotherapy. Although
this study was limited by the small number of cases and short fol-
low-up periods after operation, the results indicate that c-MYC
expression might be an early recurrence predictive marker for colo-
rectal cancer patients following 5-FU-based adjuvant chemotherapy.
Recent studies have indicated that MYCN regulates the transcription
of specific ABC transporter genes in neuroblastoma [12], and that
c-MYC regulates the expression of ABC transporter genes in
chronic myelogenous leukaemia [13]. Given that ABC transporters
contribute to the resistance to chemotherapeutic agents by causing
the efflux of anti-cancer drugs, we have been suggested that c-
MYC increases 5-FU resistance in human colon cancer cells by reg-
ulating the expression of ABC transporters. To identify the ABC
transporter genes regulated by c-MYC in human colon cancer cells,
we investigated the effect of c-MYC knockdown on MDR1, MRP1,
A B
C
Fig. 3 Regulation of ABCB5 expression through c-MYC binding to the ABCB5 promoter region. (A) Total RNAs were purified from COLO-320 cells
transfected with scrambled siRNA or c-MYC siRNA, and c-MYC, MDR1, MRP1, ABCB5, ABCC4, ABCC5 and GAPDH expression levels were detected
by RT-PCR. The number under each band in the right lane shows the ratio of c-MYC, MDR1, MRP1, ABCB5, ABCC4 or ABCC5 to GAPDH band
intensity normalized to the values obtained in control cells. (B) Schema of the putative c-MYC-binding sites within the ABCB5 promoter region. The
numbered black arrow, putative c-MYC binding site; bent arrow and open box, transcription start site. Homo sapiens BAC clone from human chro-
mosome 7 and coordinates (bp) are also presented. (C) A ChIP assay was performed on COLO-320 cells in which endogenous c-MYC protein is
expressed. The numbers on the left correspond to the arrow numbers in B. c-MYC, mouse monoclonal anti-c-MYC antibody; IgG, normal mouse
IgG; INPUT, chromatin DNA of 1/100 quantity used in ChIP.
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ABCB5, ABCC4 and ABCC5 expression levels, which are closely
involved in the resistance to chemotherapeutic agents including 5-
FU [17–23]. Interestingly, c-MYC knockdown markedly decreased
the expression level of ABCB5, which promotes doxorubicin trans-
port [20] and is involved in 5-FU resistance [21]. Moreover, ChIP
assays revealed that c-MYC binds to two binding sites within the
ABCB5 promoter region. c-MYC inhibitor, 10058-F4, decreased the
amount of c-MYC binding to its binding site within the ABCB5 pro-
moter region and led to the decrease in ABCB5 expression at
mRNA and protein levels. Furthermore, we examined the change in
the expression levels of other 5-FU resistance-involved ABC trans-
porters, ABCC5 and ABCG2 proteins following 10058-F4 treatment.
Unexpectedly, COLO-320 cells had very low ABCC5 expression at
protein level. Although 10058-F4 treatment decreased ABCC5
expression, it appeared that the decrease in ABCC5 expression had
no effect on 5-FU resistance because of its low expression in
COLO-320 cells. As expected, ABCC5 knockdown did not decrease
survival rate following 5-FU treatment in COLO-320 cells (Fig. S1).
ABCG2 was expressed in COLO-320 cells at protein level, and
10058-F4 treatment did not decrease ABCG2 expression. ABCB5-
silenced COLO-320 cells showed a decreased survival rate following
5-FU treatment, and 5-FU-resistant Caco-2 cells presented a high
ABCB5 expression level and high survival rate following 5-FU treat-
A C
DB
Fig. 4 Effect of the c-MYC inhibitor, 10058-F4, on ABCB5 expression.
(A) ChIP analysis was performed on COLO-320 cells treated with
DMSO or the c-MYC inhibitor, 10058-F4. The number on the left cor-
responds to the arrow number in Figure 3B. The number under the
band in the second lane from the left shows the ratio of ChIP with c-
MYC to INPUT band intensity normalized to the value obtained in con-
trol cells. c-MYC, mouse monoclonal anti-c-MYC antibody; IgG, normal
mouse IgG; INPUT, chromatin DNA of 1/100 quantity used in ChIP.
(B) Total RNAs were purified from COLO-320 cells treated with DMSO
(vehicle) or 10058-F4 at various concentrations (32, 64 and 100 lM)
for 48 hrs, and ABCB5 and GAPDH expression was detected by RT-
PCR. The number under each band in the upper panel shows the ratio
of ABCB5 to GAPDH band intensity normalized to the value obtained in
control cells. (C and D) Whole cell lysates were prepared from COLO-
320 cells treated with DMSO (vehicle) or 10058-F4 at a concentration
of 64 lM for 48 hrs, and ABCB5, ABCC5, ABCG2 and a-Tubulin
expression in whole cell lysates was detected by western blotting. a-
Tubulin was used to assess the total amount of whole cell lysates
loaded on the gel. The number under the band shows the ratio of
ABCB5, ABCC5 or ABCG2 to a-Tubulin band intensity normalized to




Fig. 5 Relationship between ABCB5 expression level and 5-FU resis-
tance. (A) Whole cell lysates were prepared from COLO-320 cells trans-
fected with control siRNA or ABCB5 siRNA. ABCB5 and a-Tubulin
expression in whole cell lysates was detected by western blotting. a-
Tubulin was used to assess the total amount of whole cell lysates
loaded on the gel. The number under the band in the upper right lane
shows the ratio of ABCB5 to a-Tubulin band intensity normalized to the
value obtained in control cells. (B) COLO-320 cells transfected with
scrambled siRNA or ABCB5 siRNA were treated with DMSO (vehicle
control of 5-FU), 0.9% sodium chloride (vehicle control of cisplatin), 5-
FU (5 lM) or cisplatin (5 lM) for 48 hrs, followed by a WST-8 assay
to assess the survival rate. The survival rate was normalized to that in
the scrambled siRNA or ABCB5 siRNA transfected cells treated with
DMSO or 0.9% sodium chloride as a vehicle control. *P < 0.05, signifi-
cantly different (n = 3). (C) Whole cell lysates were prepared from
parental Caco-2 cells or 5-FU-resistant Caco-2 cells, and the ABCB5 and
a-Tubulin expression in whole cell lysates was detected by western
blotting. a-Tubulin was used to assess the total amount of whole cell
lysates loaded on the gel. The number under the band in the upper right
lane shows the ratio of ABCB5 to a-Tubulin band intensity normalized
to the value obtained in control cells. Parental, parental Caco-2 cells;
FR, 5-FU-resistant Caco-2 cells. (D) Parental Caco-2 cells or 5-FU-resis-
tant Caco-2 cells were treated with DMSO or 5-FU at a concentration of
5 lM for 72 hrs, followed by a WST-8 assay to assess the survival
rate. The survival rate was normalized to that in parental Caco-2 cells
or 5-FU-resistant Caco-2 cells treated with DMSO as a vehicle control.
*P < 0.05, significantly different (n = 3). Parental, parental Caco-2
cells; FR, 5-FU-resistant Caco-2 cells.
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ment compared with those in parental Caco-2 cells. These results
suggest that c-MYC confers resistance to 5-FU through regulating
ABCB5 expression in human colon cancer cells. Furthermore, in
vivo study showed that the combined treatment of 10058-F4 and 5-
FU significantly decreased tumorigenicity in nude mice compared
with 5-FU or 10058-F4 treatment alone. The combined treatment of
5-FU and 10058-F4 tended to decrease the Ki67-positive ratio and
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showed that the combined treatment of 5-FU and 10058-F4
increased the ratio of Annexin V- and PI-positive cells and
decreased the expression level of PCNA (Fig. S2A and B). As
expected, 10058-F4 treatment decreased the ABCB5 expression
level in spite of the presence or the absence of 5-FU treatment.
Remarkably, 5-FU treatment alone increased the ABCB5 expression
level. This finding is consistent with a recent study demonstrating
that the ABCB5 expression level is increased in rectal cancer speci-
mens from patients following 5-FU-based chemotherapy and human
colorectal cancer murine xenografts following 5-FU treatment [21].
Importantly, we observed that ABCB5 expression level in primary
colorectal cancer tissues did not correlate with the recurrence rate
following 5-FU-based adjuvant chemotherapy (Fig. S3). As
expected, there was no correlation between ABCB5 and c-MYC
expression levels in primary colorectal cancer tissues (Fig. S4).
Combined with the results that ABCB5 expression level is increased
following 5-FU treatment, we consider that low expression level
of ABCB5 in primary colorectal cancer tissues is because of a lack
of 5-FU-based adjuvant chemotherapy, and ABCB5 expression level
may be increased in recurrent colorectal cancer tissues survived
following 5-FU-based adjuvant chemotherapy. Although the mecha-
nism by which 5-FU treatment increases ABCB5 expression level
remains unknown, we propose two possibilities. One possibility is
that some population of colon cancer cells which originally have
high ABCB5 expression survive following 5-FU treatment. Another
possibility is that 50-FU treatment increases ABCB5 expression in
some population of colon cancer cells, and the colon cancer cells
with the increased ABCB5 expression can survive. A recent report
supports the latter possibility, showing that HIF-1a is up-regulated
in tumour cells in response to doxorubicin [27]. There is a possibil-
ity that 5-FU treatment enhances c-MYC activity and leads to the
induction of ABCB5 expression. Further studies are needed to eluci-
date the mechanism by which 5-FU treatment increases the ABCB5
expression level.
In this study, we showed that c-MYC confers resistance to 5-
FU by regulating ABCB5 expression in human colon cancer cells.
Our results suggest that the c-MYC-ABCB5 axis could be a
potential therapeutic target in 5-FU-resistant colorectal cancer
cells.
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Fig. 6 Effect of the combined treatment of 5-FU and 10058-F4 on human colon cancer xenografts. Nude mice were subcutaneously injected with Caco-2
cells. When the tumour volume was about 1000 mm3, the mice were treated daily with DMSO as a vehicle control, 5-FU (10 mg/kg), 10058-F4 (20 mg/
kg), or 5-FU (10 mg/kg) and 10058-F4 (20 mg/kg) for 2 weeks. Each group consisted of five mice. (A) Representative photographs of tumours follow-
ing a 14-day treatment with each reagent are shown. (B) Tumour volume was measured with a caliper, and the volume was calculated with the following
formula: tumour volume = length 9 width 9 height. The tumour volume was measured at day 0, 3, 5, 7, 10 and 14 following the daily treatment with
DMSO, 5-FU, 10058-F4, or 5-FU and 10058-F4. *P < 0.05, significantly different (n = 5). (C) Representative immunofluorescence staining of Ki67
(red) expression in human colon cancer xenografts following DMSO, 5-FU, 10058-F4, or 5-FU and 10058-F4 treatment for 14 days. Nuclei were stained
with DAPI (blue). Magnification 940; scale bars, 50 lm. (D) Quantitative analysis showed the ratio of Ki67-positive cells to DAPI-positive cells within at
least 8 randomly chosen fields. *P < 0.05, significantly different. (E) Representative immunofluorescence staining of TUNEL (red) expression in human
colon cancer xenografts following DMSO, 5-FU, 10058-F4, or 5-FU and 10058-F4 treatment for 14 days. Nuclei were stained with DAPI (blue). Magnifi-
cation 940; scale bars, 50 lm. (F) Quantitative analysis showed the ratio of TUNEL-positive cells to DAPI-positive cells within at least 8 randomly cho-
sen fields. *P < 0.05, significantly different. (G) Representative immunofluorescence analysis of ABCB5 (red) expression in human colon cancer
xenografts following DMSO, 5-FU, 10058-F4, or 5-FU and 10058-F4 treatment for 14 days. Nuclei were stained with DAPI (blue). Magnification 910
(upper half) and 940 (lower half); scale bars, 50 lm. (H) Representative western blotting analysis of ABCB5 expression in human colon cancer xeno-
grafts following DMSO, 5-FU, 10058-F4, or 5-FU and 10058-F4 treatment for 14 days. The number under each band in the upper panel shows the ratio
of ABCB5 to a-Tubulin band intensity normalized to the value obtained in control cells.
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